Human Oncology & Pathogenesis Program: Faculty

Pictured: Omar Abdel-Wahab
Omar I. Abdel-Wahab

Physician-scientist Omar Abdel-Wahab studies the functional genomics of hematopoietic malignancies.

José Baselga

Memorial Sloan Kettering Physician-in-Chief José Baselga studies mechanisms of resistance to targeted therapies and identification of novel therapeutic combinations in solid cancers.

Pictured: Michael Berger
Michael F. Berger

Researcher Michael Berger focuses on massively parallel sequencing of tumor DNA for biomarker discovery and clinical diagnostics.

Cameron W. Brennan

Physician-scientist Cameron Brennan focuses on genomic analysis of human and mouse gliomas and medulloblastomas.

Pictured: Timothy Chan
Timothy A. Chan

Physician-scientist Timothy Chan focuses on the identification and characterization of tumor suppressors in glioblastoma and breast cancer.

Pictured: Sarat Chandarlapaty
Sarat Chandarlapaty

Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.

Pictured: Yu Chen
Yu Chen

Physician-scientist Yu Chen studies the role of transcription factors that are critical for prostate cancer development.

Emily H. Cheng

Physician-scientist Emily Cheng focuses on the molecular mechanisms of cell death and their implications in tumorigenesis and cancer therapy, with primary emphasis on lung and kidney cancers.

Pictured: Ping Chi
Ping Chi

Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic transcription factors in GIST and other solid tumors.

Pictured: James Fagin
James A. Fagin

Physician-scientist James Fagin focuses on the pathogenesis of thyroid cancer and the role of oncogenic kinases.

Pictured: James J. Hsieh
James J. Hsieh

Physician-scientist James Hsieh focuses on developing novel therapeutics targeting cancer cell proliferation; he also directs Memorial Sloan Kettering’s translational kidney cancer research program.

Pictured: Jason T. Huse
Jason T. Huse

Physician-scientist Jason Huse focuses on the molecular pathogenesis of brain tumors, particularly high-grade gliomas.

Pictured: Christine Iacobuzio-Donahue
Christine A. Iacobuzio-Donahue

Physician-scientist Christine Iacobuzio-Donahue studies the genomics and cell biology of pancreatic and other solid tumors as it relates to subclonal evolution, tumor progression, and metastasis.

Pictured: Marc Ladanyi
Marc Ladanyi

Molecular pathologist Marc Ladanyi studies the molecular pathogenesis of sarcomas, lung cancer, and mesothelioma.

Pictured: Steven D. Leach, MD
Steven D. Leach

Physician-scientist Steven Leach studies molecular, genetic, and cellular determinants of pancreatic cancer initiation and progression.

Pictured: Ross Levine
Ross L. Levine

Physician-scientist Ross Levine focuses on the investigation of genetic basis of hematopoietic malignancies.

Pictured: Ingo Mellinghoff
Ingo K. Mellinghoff

Physician-scientist Ingo Mellinghoff studies signal transduction alterations in primary brain tumors.

Pictured: Christopher Park
Christopher Y. Park

Physician-scientist Christopher Park focuses on the identification and characterization of molecular pathways that regulate normal and malignant stem cells in the hematopoietic system.

Pictured: Jorge S. Reis-Filho
Jorge S. Reis-Filho

Physician-scientist Jorge Reis-Filho focuses on the development of a predictive molecular classification for rare types of breast cancer and characterization of intratumor genetic heterogeneity in breast cancers.

Charles L. Sawyers

Human Oncology and Pathogenesis Program Chair Charles Sawyers develops molecularly targeted cancer therapy.

Nikolaus Schultz
Nikolaus Schultz

Cancer biologist Nikolaus Schultz uses computational tools to study the diversity of genomic alterations underlying different cancer types.

Pictured: David Solit
David B. Solit

Physician-scientist David Solit studies human oncology and pathogenesis, genomics, oncogenes and tumor suppressors, cancer therapeutics, and clinical trials.

Pictured: Barry Taylor
Barry S. Taylor

Researcher Barry Taylor focuses on defining the somatic abnormalities that mediate the genesis, progression, and response to therapy of human cancers.